… the effect of therapeutic anticoagulation with heparin vs. prophylactic anticoagulation on the
rate of thrombotic events and mortality, … apixaban or placebo did not change the main study …

… cases and over 2,500,000 deaths.Recent observations … Enoxaparin was the first low
molecular weight heparin to be … findings of anticoagulation dosing regimens in COVID-19 but …

… anticoagulation for all hospitalized patients with COVID‐19, with most recommending use of
low‐molecular‐weight heparin or unfractionated heparin. … of 460 000 deaths worldwide as of …

… therapeutic anticoagulation with mortality for patients with COVID-19 … Therapeutic
anticoagulation was defined as apixaban, … anticoagulation was defined as subcutaneous heparin …

… COVID-19, contributing to significant morbidity and mortality [… anticoagulation, mainly
heparin, in hospitalized COVID-19 … dose aspirin, 2.5 mg apixaban, 5 mg apixaban, and placebo. …

… and deaths among outpatients with symptomatic COVID-19. … heparin in symptomatic outpatients
with COVID-19. We compared … use of anticoagulants in outpatients with COVID-19, as it …

… The efficacy of low-molecular-weight heparin (LMWH) doses … risk of mortality in patients
with the severe form of COVID-19 [… and Apixaban) in four out of five hospitalized COVID-19 …

… two doses of apixaban for patients with COVID-19 infection who … heparin (UFH) unless
specific contraindications exist. … The mortality rate in children hospitalized with COVID-19 or MIS-…

… apixaban, rivaroxaban or edoxaban for at least 1 year before … with COVID-19 was associated
with increased mortality … patients with prior DOAC therapy will be switched to heparins …

… anticoagulation (pAC) to be associated with lower mortality at … –4) or direct oral anticoagulants
(apixaban and rivaroxaban). … used anticoagulant was intravenous unfractionated heparin (…